File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Metabolomic Profiling of Plasma from Patients with Tuberculosis by Use of Untargeted Mass Spectrometry Reveals Novel Biomarkers for Diagnosis

TitleMetabolomic Profiling of Plasma from Patients with Tuberculosis by Use of Untargeted Mass Spectrometry Reveals Novel Biomarkers for Diagnosis
Authors
Issue Date2015
PublisherAmerican Society for Microbiology. The Journal's web site is located at http://jcm.asm.org/
Citation
Journal of Clinical Microbiology, 2015, v. 53 n. 12, p. 3750-3759 How to Cite?
AbstractAlthough tuberculosis (TB) is a reemerging disease that affects people in developing countries and immunocompromised populations in developed countries, the current diagnostic methods are far from optimal. Metabolomics is increasingly being used for studies on infectious diseases. We performed metabolome profiling of plasma samples to identify potential biomarkers for diagnosing TB. We compared the plasma metabolome profiles of TB patients (n = 46) with those of community-acquired pneumonia (CAP) patients (n = 30) and controls without active infection (n = 30) using ultrahigh-performance liquid chromatography–electrospray ionization-quadrupole time of flight mass spectrometry (UHPLC-ESI-QTOFMS). Using multivariate and univariate analyses, four metabolites, 12R-hydroxy-5Z,8Z,10E,14Z-eicosatetraenoic acid [12(R)-HETE], ceramide (d18:1/16:0), cholesterol sulfate, and 4α-formyl-4β-methyl-5α-cholesta-8-en-3β-ol, were identified and found to have significantly higher levels in TB patients than those in CAP patients and controls. In a comparison of TB patients and controls, the four metabolites demonstrated area under the receiver operating characteristic curve (AUC) values of 0.914, 0.912, 0.905, and 0.856, sensitivities of 84.8%, 84.8%, 87.0%, and 89.1%, specificities of 90.0%, 86.7%, 86.7%, and 80.0%, and fold changes of 4.19, 26.15, 6.09, and 1.83, respectively. In a comparison of TB and CAP patients, the four metabolites demonstrated AUC values of 0.793, 0.717, 0.802, and 0.894, sensitivities of 89.1%, 71.7%, 80.4%, and 84.8%, specificities of 63.3%, 66.7%, 70.0%, and 83.3%, and fold changes of 4.69, 3.82, 3.75, and 2.16, respectively. 4α-Formyl-4β-methyl-5α-cholesta-8-en-3β-ol combined with 12(R)-HETE or cholesterol sulfate offered ≥70% sensitivity and ≥90% specificity for differentiating TB patients from controls or CAP patients. These novel plasma biomarkers, especially 12(R)-HETE and 4α-formyl-4β-methyl-5α-cholesta-8-en-3β-ol, alone or in combination, are potentially useful for rapid and noninvasive diagnosis of TB. The present findings may offer insights into the pathogenesis and host response in TB.
Persistent Identifierhttp://hdl.handle.net/10722/229684
ISSN
2023 Impact Factor: 6.1
2023 SCImago Journal Rankings: 1.653
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLau, SKP-
dc.contributor.authorLee, KC-
dc.contributor.authorCurreem, SOT-
dc.contributor.authorChow, WN-
dc.contributor.authorTo, KKW-
dc.contributor.authorHung, FNI-
dc.contributor.authorHo, DT-
dc.contributor.authorSridhar, S-
dc.contributor.authorLi, WS-
dc.contributor.authorDing, SY-
dc.contributor.authorKoo, EW-
dc.contributor.authorWong, CF-
dc.contributor.authorTam, S-
dc.contributor.authorLam, CW-
dc.contributor.authorYuen, KY-
dc.contributor.authorWoo, PCY-
dc.date.accessioned2016-08-23T14:12:39Z-
dc.date.available2016-08-23T14:12:39Z-
dc.date.issued2015-
dc.identifier.citationJournal of Clinical Microbiology, 2015, v. 53 n. 12, p. 3750-3759-
dc.identifier.issn0095-1137-
dc.identifier.urihttp://hdl.handle.net/10722/229684-
dc.description.abstractAlthough tuberculosis (TB) is a reemerging disease that affects people in developing countries and immunocompromised populations in developed countries, the current diagnostic methods are far from optimal. Metabolomics is increasingly being used for studies on infectious diseases. We performed metabolome profiling of plasma samples to identify potential biomarkers for diagnosing TB. We compared the plasma metabolome profiles of TB patients (n = 46) with those of community-acquired pneumonia (CAP) patients (n = 30) and controls without active infection (n = 30) using ultrahigh-performance liquid chromatography–electrospray ionization-quadrupole time of flight mass spectrometry (UHPLC-ESI-QTOFMS). Using multivariate and univariate analyses, four metabolites, 12R-hydroxy-5Z,8Z,10E,14Z-eicosatetraenoic acid [12(R)-HETE], ceramide (d18:1/16:0), cholesterol sulfate, and 4α-formyl-4β-methyl-5α-cholesta-8-en-3β-ol, were identified and found to have significantly higher levels in TB patients than those in CAP patients and controls. In a comparison of TB patients and controls, the four metabolites demonstrated area under the receiver operating characteristic curve (AUC) values of 0.914, 0.912, 0.905, and 0.856, sensitivities of 84.8%, 84.8%, 87.0%, and 89.1%, specificities of 90.0%, 86.7%, 86.7%, and 80.0%, and fold changes of 4.19, 26.15, 6.09, and 1.83, respectively. In a comparison of TB and CAP patients, the four metabolites demonstrated AUC values of 0.793, 0.717, 0.802, and 0.894, sensitivities of 89.1%, 71.7%, 80.4%, and 84.8%, specificities of 63.3%, 66.7%, 70.0%, and 83.3%, and fold changes of 4.69, 3.82, 3.75, and 2.16, respectively. 4α-Formyl-4β-methyl-5α-cholesta-8-en-3β-ol combined with 12(R)-HETE or cholesterol sulfate offered ≥70% sensitivity and ≥90% specificity for differentiating TB patients from controls or CAP patients. These novel plasma biomarkers, especially 12(R)-HETE and 4α-formyl-4β-methyl-5α-cholesta-8-en-3β-ol, alone or in combination, are potentially useful for rapid and noninvasive diagnosis of TB. The present findings may offer insights into the pathogenesis and host response in TB.-
dc.languageeng-
dc.publisherAmerican Society for Microbiology. The Journal's web site is located at http://jcm.asm.org/-
dc.relation.ispartofJournal of Clinical Microbiology-
dc.titleMetabolomic Profiling of Plasma from Patients with Tuberculosis by Use of Untargeted Mass Spectrometry Reveals Novel Biomarkers for Diagnosis-
dc.typeArticle-
dc.identifier.emailLau, SKP: skplau@hkucc.hku.hk-
dc.identifier.emailTo, KKW: kelvinto@hkucc.hku.hk-
dc.identifier.emailHung, FNI: ivanhung@hkucc.hku.hk-
dc.identifier.emailSridhar, S: sid8998@hku.hk-
dc.identifier.emailLi, WS: liws03@hku.hk-
dc.identifier.emailDing, SY: sydin1@hku.hk-
dc.identifier.emailTam, S: stam@hkucc.hku.hk-
dc.identifier.emailLam, CW: ching-wanlam@pathology.hku.hk-
dc.identifier.emailYuen, KY: kyyuen@hkucc.hku.hk-
dc.identifier.emailWoo, PCY: pcywoo@hkucc.hku.hk-
dc.identifier.authorityLau, SKP=rp00486-
dc.identifier.authorityTo, KKW=rp01384-
dc.identifier.authorityHung, FNI=rp00508-
dc.identifier.authorityLam, CW=rp00260-
dc.identifier.authorityYuen, KY=rp00366-
dc.identifier.authorityWoo, PCY=rp00430-
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1128/JCM.01568-15-
dc.identifier.pmid26378277-
dc.identifier.pmcidPMC4652110-
dc.identifier.scopuseid_2-s2.0-84947782969-
dc.identifier.hkuros262224-
dc.identifier.volume53-
dc.identifier.issue12-
dc.identifier.spage3750-
dc.identifier.epage3759-
dc.identifier.isiWOS:000367532800008-
dc.publisher.placeUnited States-
dc.identifier.issnl0095-1137-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats